Assessment of G6PD screening program in premature infants in a NICU.
OBJECTIVE
Targeted screening for glucose-6-phosphate dehydrogenase deficiency (G6PDdef) using fluorescent spot test (FST) is done in our newborn nursery (NN) and now in our NICU. Premature infants have higher G6PD levels than term infants. FST may result in under diagnosis of G6PDdef in preterms. We sought to determine if FST is appropriate for diagnosis of G6PDdef at<35 weeks and assess screening in NICU.


METHODS
Retrospective chart review of male, inborn infants<35 weeks in NICU from 2008 to 2011. Difference in G6PDdef incidence<5% between NN and NICU was acceptable for equivalence.


RESULTS
Out of 679 subjects, 442 were screened for G6PDdef and 11.3% had abnormal results. Binomial testing comparing 11.3% (95% confidence interval (CI) 8.5 to 14.6) incidence of G6PDdef in NICU and reported incidence in NN (11%) demonstrated no difference. 12.2% of Black/African American males were not screened.


CONCLUSIONS
FST is appropriate for screening all at-risk newborns. A number of at-risk premature males were not screened.
Division of Neonatology, Department of Pediatrics, Oregon Health and Science University, Doernbecher Children's Hospital, Portland, OR, USA.
R
R
Lam
Center for Clinical Investigation, Case Western Reserve University, Cleveland, OH, USA.
H
H
Li
Division of Neonatology, Department of Pediatrics, University Hospitals Case Medical Center Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
M L
ML
Nock
D005260:Female; D005312:Fetal Blood / Q000201:enzymology*; D005954:Glucosephosphate Dehydrogenase / Q000097:blood; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000175:diagnosis* / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood*; D007363:Intensive Care Units, Neonatal; D008297:Male; D015997:Neonatal Screening; D009820:Ohio; D012189:Retrospective Studies
D005954:Glucosephosphate Dehydrogenase